Neurogene Inc. is a biotechnology company focused on developing innovative gene therapies for rare neurological diseases
The company aims to address the underlying genetic causes of these conditions by employing cutting-edge science and technology to create targeted treatments that have the potential to improve the lives of patients. Through its research and development efforts, Neurogene seeks to advance the understanding and treatment of neurogenetic disorders, offering hope to individuals and families affected by these challenging ailments.
Neurogene has been on a huge run in 2024. That came to a halt after the company released trial results. But, the results may be better than the market thinks.
